3rd Circ. Signals Disapproval Of Lamictal Antitrust Class Cert.
The Third Circuit questioned a district court's certification of a class of drug wholesalers who lodged pay-for-delay claims against GlaxoSmithKline PLC and Teva Pharmaceuticals Ltd. over the generic version of the...To view the full article, register now.
Already a subscriber? Click here to view full article